SCHEMBL548189

SCHEMBL548189

COc1ccc(C=O)c(C(=O)O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.61
TYR P14679 1/20 0.61
TRIM33 Q9UPN9 1/20 0.61
ALDH1A1 P00352 5/20 0.58
ERN1 O75460 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
KDM4E B2RXH2 5/20 0.54
POLB P06746 4/20 0.54
LMNA P02545 2/20 0.54
HPGD P15428 1/20 0.54
HSD17B10 Q99714 1/20 0.54
AKR1C3 P42330 4/20 0.48
AKR1C2 P52895 4/20 0.48
MEN1 O00255 2/20 0.47
MAPT P10636 2/20 0.47
KMT2A Q03164 2/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
SLC16A3 O15427 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29955976 1.00 TRIM24 (0.61) TRIM24TYRTRIM33ALDH1A1ERN1
SCHEMBL13329535 0.86 TRIM24 (0.61) TRIM24TYRTRIM33ALDH1A1ERN1
SCHEMBL4733806 0.86 ERN1 (0.61) TRIM24TYRTRIM33ALDH1A1ERN1
SCHEMBL4476198 0.84 TRIM24 (0.59) TRIM24TYRTRIM33ALDH1A1ERN1
SCHEMBL12837795 0.84 SMN1; SMN2 (0.54) TRIM24TYRTRIM33ALDH1A1SMN1; SMN2
SCHEMBL7302719 0.84 TRIM24 (0.59) TRIM24TYRTRIM33ALDH1A1ERN1
SCHEMBL10457145 0.83 KDM4E (0.58) ALDH1A1SMN1; SMN2KDM4ELMNAHPGD
SCHEMBL7235657 0.82 ALDH1A1 (0.61) TRIM24TYRTRIM33ALDH1A1ERN1
SCHEMBL29956204 0.81 TRIM24 (0.56) TRIM24TYRTRIM33ALDH1A1ERN1
SCHEMBL11530087 0.81 TRIM24 (0.56) TRIM24TYRTRIM33ALDH1A1ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118580016-A Nicotinamide ribochlorate-based salicylaldehyde functional molecule hybridized natural brucite-based composite powder, and preparation method and application thereof 江西广源化工有限责任公司 2024-09-03 CN claimed
EP-2080750-B1 RADIATION-SENSITIVE COMPOSITION MITSUBISHI GAS CHEMICAL CO (JP) 2020-07-29 EP claimed
CN-118580205-A Use of PSF-LncRNA interaction inhibitor in preparation of medicine for treating cancer 山东铂源药业股份有限公司 2024-09-03 CN disclosed
CN-118580016-A Nicotinamide ribochlorate-based salicylaldehyde functional molecule hybridized natural brucite-based composite powder, and preparation method and application thereof 江西广源化工有限责任公司 2024-09-03 CN disclosed
CN-105593224-B Novel quinazolinones as bromodomain inhibitors 恒元生物医药科技(苏州)有限公司 2021-05-25 CN disclosed
CN-108008600-B Radiation-sensitive composition 三菱瓦斯化学株式会社 2021-02-09 CN disclosed
EP-2080750-B1 RADIATION-SENSITIVE COMPOSITION MITSUBISHI GAS CHEMICAL CO (JP) 2020-07-29 EP disclosed
EP-3027604-B1 NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS ZENITH EPIGENETICS LTD (CA) 2019-02-20 EP disclosed
US-10000488-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-19 US disclosed
US-20180092924-A1 NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS RVX THERAPEUTICS INC. (CA) 2018-04-05 US disclosed
US-9897913-B2 Radiation-sensitive composition MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2018-02-20 US disclosed
EP-0420808-B1 Pyran-containing phthalides CIBA GEIGY AG (CH) 1995-03-01 EP disclosed
CN-1072677-A Aromatic amidine derivative and salt thereof DAIICHI SEIYAKU CO (JP) 1993-06-02 CN disclosed
US-5210232-A Pyran-containing phthalides CIBA-GEIGY CORPORATION (US) 1993-05-11 US disclosed
EP-0540051-A1 Aromatic amidine derivatives and salts thereof DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1993-05-05 EP disclosed
US-5097044-A PYRAN-CONTAINING PHTHALIDES CIBA-GEIGY CORPORATION (US) 1992-03-17 US disclosed
EP-0437185-A2 Pyrroline-resp. indoline containing phthalides CIBA-GEIGY AG (CH) 1991-07-17 EP disclosed
EP-0420808-A2 Pyran-containing phthalides CIBA-GEIGY AG (CH) 1991-04-03 EP disclosed
US-4018891-A INHIBITORS OF ANTIGEN-ANTIBODY REACTIONS RICHARDSON-MERRELL INC. (US) 1977-04-19 US disclosed
US-3960892-A ANTIGEN-ANTIBODY REACTION INHIBITION RICHARDSON-MERRELL INC. (US) 1976-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180092924-A1 NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRDT TRIM24 458/4885TYR 4338/4885TRIM33 823/4885
US-10000488-B2 Heterocyclic compound RORC, RORB, RORA TRIM24 1501/4885TYR 2795/4885TRIM33 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.